Nivolumab for Head and Neck Cancer

Palo Alto (17 mi)

Overseen byTrisha Wise-Draper, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Trisha Wise-Draper

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 4 jurisdictions

Trial Summary

What is the purpose of this trial?The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.

Eligibility Criteria

This trial is for individuals who have had head and neck cancer, were treated with radiation (and possibly chemotherapy), and then underwent surgery to remove the cancer. They should be in good health otherwise, able to undergo scans, provide tissue samples, and have no other treatment options.

Treatment Details

The study is examining the effectiveness of Nivolumab as an additional treatment after surgical removal of head and neck cancer in patients who've already received radiation therapy. It aims to see if this drug can improve outcomes post-surgery.

1Treatment groups

Experimental Treatment

Group I: NivolumabExperimental Treatment1 Intervention

Nivolumab starting 4-11 weeks after surgery for 6 doses.